Suven Life Sciences shines on initiating phase 2A trial of SUVN-502 in USA in Alzheimer’s Disease

07 Dec 2015 Evaluate

Suven Life Sciences is currently trading at Rs. 269.05, up by 8.20 points or 3.14% from its previous closing of Rs. 260.85 on the BSE.

The scrip opened at Rs. 262.00 and has touched a high and low of Rs. 272.55 and Rs. 260.00 respectively. So far 116250 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 192.15 on 08-Sep-2015.

Last one week high and low of the scrip stood at Rs. 273.25 and Rs. 259.50 respectively. The current market cap of the company is Rs. 3363.44 crore.

The promoters holding in the company stood at 59.57% while Institutions and Non-Institutions held 7.20% and 33.23% respectively.

Suven Life Sciences, a clinical stage biopharmaceutical company developing novel medicines to treat life-threatening Central Nervous System (CNS) disorders, has initiated dose administration of the first patient in a Phase 2A clinical trial of SUVN-502, a 5HT6 antagonist in patients with moderate Alzheimer’s Disease (AD). The clinical development program being executed through Suven, Inc., a Delaware Company in USA, wholly owned subsidiary of Suven Life Sciences.

This trial is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of SUVN-502 for the treatment of moderate Alzheimer’s Disease (AD).

This trial is expected to enroll 537 patients and the primary objective of the study is to evaluate the efficacy of a serotonin receptor subtype 6 (5-HT6) antagonist, SUVN-502, at daily doses of 50 mg or 100 mg compared to placebo, as adjunct treatment in subjects with moderate Alzheimer’s disease (Mini-Mental State Examination [MMSE] score of 12 to 20) currently treated with the acetylcholinesterase inhibitor, Donepezil Hydrochloride (HCI) and the N-methyl-D-aspartic acid (NMDA) antagonist, MemantineHCI. Efficacy will be assessed by the 11-item Alzheimer’s Disease Assessment Scale for Cognitive Behavior (ADAScog-11) after 26 weeks of treatment. The trial is likely to complete by end of second quarter 2017, subject to the achievement of estimated 12 months’ enrollment goal in USA.

Secondary objectives are to further evaluate the efficacy of these treatments using scales i.e. Clinical Dementia Rating (CDR) Scale, Sum of Boxes (CDR-SB), MMSE, Alzheimer’s Disease Co-operative Study Activity of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI) 12 item and Cornell Scale for Depression and Dementia (C-SDD) and this study is being coordinated by Dr. Jeffrey Cummings, MD, Director, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

170.15 -1.25 (-0.73%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×